Company Focus
Galderma
Latest Galderma News
Pharmaceutical
Swiss dermatology company Galderma is expanding its premium regenerative skincare brand Alastin across the Japan and Asia Pacific (JPAC) region, deepening its bet on one of the world's fastest-growing aesthetics markets. 20 July 2026
Dermatology News
Insights
Company Spotlight
Latest News & Features of interest to Galderma
Biotechnology
Swiss biotech firm MoonLake Immunotherapeutics said on Monday that sonelokimab met all clinical endpoints at week 16 in the Phase III IZAR-1 trial in psoriatic arthritis (PsA). Shares fell about 6% on the day, as the company held back the one comparison investors were waiting for. 11 August 2026
Pharmaceutical
Swiss dermatology company Galderma is expanding its premium regenerative skincare brand Alastin across the Japan and Asia Pacific (JPAC) region, deepening its bet on one of the world's fastest-growing aesthetics markets. 20 July 2026
Pharmaceutical
Skin disease is one of the most common health challenges in the world. More than a third of the global population lives with a dermatological condition, ranging from the chronic and inflammatory to the infectious and rare. And yet dermatology remains a field where significant gaps persist: in access, in diagnosis, in conversations at doctor’s offices, and critically, in how well the solutions available reflect the needs of those living with the conditions. 8 June 2026
Pharmaceutical
US biopharma company ARS Pharmaceuticals has announced the appointment of Donn Casale as president, effective June 1, 2026. Richard Lowenthal will continue to lead ARS Pharma as chief executive (CEO). 14 May 2026
Pharmaceutical
Spanish drugmaker Almirall has reported first-quarter 2026 results in line with expectations, driven by continued strong momentum in its European dermatology business and biologics portfolio. 11 May 2026
Biotechnology
Avalo Therapeutics’ shares surged 34%, after the US clinical-stage biotech announced positive top-line results from its Phase II LOTUS trial evaluating the efficacy and safety of abdakibart in adults with moderate to severe hidradenitis suppurativa (HS). 8 May 2026
Biotechnology
Norway’s Lytix Biopharma announced that new Phase II clinical data on ruxotemitide, also known as VP-315, will be presented by its partner Verrica Pharmaceuticals at the 2026 Society for Investigative Dermatology SID) Annual Meeting. 6 May 2026
Biotechnology
Privately-held Windward Bio, a Swiss biotech focused on serious immunological diseases, has announced an upsized $165 million crossover financing. 5 May 2026
Pharmaceutical
German generics, biosimilars and consumer healthcare major STADA Arzneimittel says it has reinforced its status as a partner of choice and top-five player in European consumer healthcare by acquiring commercial rights to the Locobase skincare range in Denmark, Sweden, Norway, Finland and Iceland. 5 May 2026
Biotechnology
Danish dermatology specialist LEO Pharma today said it has entered into a definitive agreement to acquire Replay, a US gene therapy company focused on developing transformative treatments for rare genetic dermatological conditions. 30 April 2026
Latest In Brief for Galderma
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze